| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Vol. 52, Issue 1, 1-10, March 2000
Section of Endocrinology, Veterans Affairs Medical Center,
Phoenix, Arizona
I. Introduction
II. Short-Acting Insulin Analogs
A. Insulin Asp(B10)
B. Insulin Lispro
C. Insulin Aspart
III. Long-Acting Insulin Analogs
A. NovoSol Basal
B. HOE 901
C. Fatty Acid Acylated Insulins
IV. Future Directions
A. Increased Stability
B. Less Variability
C. Selective Action
D. Ultra Rapid Onset
E. Ultra Long Activity
F. Benefit without Metabolic Activity?
V. Closing Thoughts
References
Tight glucose control is essential to minimize complications in diabetic patients. However, the pharmacokinetic characteristics of the currently available rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. Until recently, improvements in insulin formulations were seriously limited as advances were only achieved in insulin purity, species, and characteristics of the retarding agent. The availability of molecular genetic techniques opened new windows to create insulin analogs by changing the structure of the native protein and to improve the therapeutic properties. The first clinically available insulin analog, Lispro, confirmed the hopes by showing that improved glycemic control can be achieved without an increase in hypoglycemic events. This requires, however, optimal basal insulin replacement, either by multiple daily injections of neutral protein Hagedorn (NPH) insulin or by insulin pump. Evidence suggests that short-acting insulin analogs would be better matched by a true basal insulin than by the erratically absorbed and rather short-acting NPH insulin. Therefore, future availability of long-acting analogs raises the hope to realize the true potential benefits of the currently available short-acting analog, Lispro, and of those still awaiting approval. The introduction of new short-acting and the first truly long-acting analogs, the development of analogs with increased stability, less variability and perhaps selective action will help to develop more individualized treatment strategies targeted to specific patient characteristics and to achieve further improvements in glycemic control.
This article has been cited by other articles:
|
|
 |
|
  T. P. Ciaraldi, S. A. Phillips, L. Carter, V. Aroda, S. Mudaliar, and R. R. Henry Effects of the Rapid-Acting Insulin Analog Glulisine on Cultured Human Skeletal Muscle Cells: Comparisons with Insulin and Insulin-Like Growth Factor I J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5551 - 5558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Peter, S. D. Luzio, G. Dunseath, A. Miles, B. Hare, K. Backx, V. Pauvaday, and D. R. Owens Effects of Exercise on the Absorption of Insulin Glargine in Patients With Type 1 Diabetes Diabetes Care, March 1, 2005; 28(3): 560 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Duttaroy, P. Kanakaraj, B. L. Osborn, H. Schneider, O. K. Pickeral, C. Chen, G. Zhang, S. Kaithamana, M. Singh, R. Schulingkamp, et al. Development of a Long-Acting Insulin Analog Using Albumin Fusion Technology Diabetes, January 1, 2005; 54(1): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Devendra, E. Liu, and G. S Eisenbarth Type 1 diabetes: recent developments BMJ, March 27, 2004; 328(7442): 750 - 754. [Full Text] [PDF]
|
|
|
|
|
|
I. Rakatzi, S. Ramrath, D. Ledwig, O. Dransfeld, T. Bartels, G. Seipke, and J. Eckel A Novel Insulin Analog With Unique Properties: LysB3,GluB29 Insulin Induces Prominent Activation of Insulin Receptor Substrate 2, but Marginal Phosphorylation of Insulin Receptor Substrate 1 Diabetes, September 1, 2003; 52(9): 2227 - 2238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Doyle and J. M. Egan Pharmacological Agents That Directly Modulate Insulin Secretion Pharmacol. Rev., March 1, 2003; 55(1): 105 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hofmann, G. Horstmann, and I. Stammberger Evaluation of the Reproductive Toxicity and Embryotoxicity of Insulin Glargine (LANTUS) in Rats and Rabbits International Journal of Toxicology, May 1, 2002; 21(3): 181 - 189. [Abstract] [PDF]
|
|
|
|
|
|
T. P. Ciaraldi, L. Carter, G. Seipke, S. Mudaliar, and R. R. Henry Effects of the Long-Acting Insulin Analog Insulin Glargine on Cultured Human Skeletal Muscle Cells: Comparisons to Insulin and IGF-I J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5838 - 5847. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
